Pay in 4 interest-free payments of $6.57 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Exploration of new incretin-based therapies
Thyroid Tumors: Theres a risk of thyroid C-cell tumors
as well as (3) current attempts in targeting the IGF-1R as a potential option in cancer therapy
GLP-1: New Metrics, New Molecules, New Prices Topics We Cover: 00:00 New data from Harvard/Mass General may classify nearly 70% of adults as having obesity 03:00 A new oral triple agonist shows record-setting absorption rates 07:00 Fractal Healths Revita procedure: weight maintenance after stopping GLP-1s 12:00 Zepbound vial prices drop (full breakdown by dose) 16:00 Daves personal experience switching off Mounjaro and intense hunger return 22:00 Novo Nordisks EVOKE/EVOKE+ Alzheimers trial: what the data really means 29:00 Why GLP-1 neurological research is just getting started 33:00 Updates on access, partners, and major news coming soon for Medicare patients If youre on Wegovy, Mounjaro, Zepbound, Saxenda, Trulicity, or compounded versions, this episode gives you the insight and context you need to have more competent and confident conversations with your doctor
